Teva EVP Fox sells 7,924 shares after RSU vesting

Teva Pharmaceutical Industries Ltd EVP, U.S. Commercial Christine Fox reported RSU vesting and related share transactions.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd EVP, U.S. Commercial Christine Fox reported RSU vesting and related share transactions. On March 5, 2026, 17,819 restricted share units were exercised into the same number of ordinary shares at a stated price of $0.00 per share.

On the same date, she sold 7,924 ordinary shares at a weighted average price of $31.6684 per share to cover tax withholding obligations, under a Rule 10b5-1 trading plan adopted on August 11, 2025. Following these transactions, she directly held 84,905 ordinary shares.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Fox Christine

Role EVP, U.S. Commercial

Sold 7,924 shs ($251K)

Approx. gross sale proceeds $251K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	17,819	$0.00	$0.00
Exercise	Ordinary Shares	17,819	$0.00	$0.00
Sale	Ordinary Shares	7,924	$31.6684	$251K

Holdings After Transaction: Restricted Share Units — 53,459 contracts (Direct); Ordinary Shares — 84,905 shares (Direct)

Footnotes (6)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. F3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
4. F4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
6. F6. Restricted share units were granted on March 5, 2025, with 17,819 vested on March 5, 2026, 17,819 vesting on each of March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Teva (TEVA) executive Christine Fox report in this Form 4?

Christine Fox reported RSU vesting and related share transactions. 17,819 restricted share units converted into ordinary shares, and 7,924 shares were sold. These movements reflect equity-based compensation activity and associated tax withholding, not an open-market discretionary purchase.

How many Teva (TEVA) shares did Christine Fox sell and at what price?

She sold 7,924 ordinary shares at a weighted average price of $31.6684. The filing notes these were multiple trades between $31.26 and $32.34 per share, and the weighted figure summarizes the overall execution range reported.

Why were shares sold by Christine Fox in the Teva (TEVA) Form 4 filing?

The filing states the 7,924 shares sold represented the amount required to cover tax withholding obligations tied to RSU vesting. This means the sale was connected to satisfying tax liabilities arising when restricted share units settled into ordinary shares.

What RSU activity for Teva (TEVA) did Christine Fox disclose?

She disclosed that 17,819 restricted share units vested and converted into ordinary shares on March 5, 2026. Footnotes explain each RSU is a contingent right to receive one ordinary share or its cash value, subject to the company’s Human Resources and Compensation Committee decisions.

How many Teva (TEVA) shares does Christine Fox hold after these transactions?

After the reported transactions, Christine Fox directly held 84,905 ordinary shares. This figure reflects her ownership following both the conversion of restricted share units into ordinary shares and the sale of shares to cover associated tax withholding obligations.

How are Teva (TEVA) ordinary shares and American Depositary Shares related in this filing?

The filing notes Teva’s ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share. This means U.S. investors trading ADSs are effectively trading interests in the same underlying ordinary shares.

What Rule 10b5-1 information is disclosed in Teva (TEVA) executive Christine Fox’s Form 4?

The document states the reported transaction was effected under a Rule 10b5-1 trading plan adopted on August 11, 2025. Such plans pre-establish trading instructions, allowing insiders to sell shares according to predetermined terms independent of later material nonpublic information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Christine

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, U.S. Commercial

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		17,819	A	(2)	92,829	D
Ordinary Shares(1)	03/05/2026		S(3)		7,924(4)	D	$31.6684(5)	84,905	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			17,819	(6)	(6)	Ordinary Shares(1)	17,819	$0	53,459	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on March 5, 2025, with 17,819 vested on March 5, 2026, 17,819 vesting on each of March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029.

	/s/ Dov Bergwerk as attorney-in-fact for Christine Fox	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.